Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

Irene Cavattoni, Heike Schieder, Tatjana Zabelina, Ulrike Bacher, Francis Ayuk, Christine Wolschke, Axel R. Zander, Nikolaus Kroeger, MD

Blood (2008) 112 (11): 4304.

https://doi.org/10.1182/blood.V112.11.4304.4304

Published: 2008

Journal Articles

Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.

Nicolaus Kroeger, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Djordje Atanackovic, MD, Heike Schieder, MD, Helmut Renges, MD, Axel R. Zander, MD

Blood (2005) 106 (11): 2010.

https://doi.org/10.1182/blood.V106.11.2010.2010

Published: 2005

Journal Articles

Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.

Joachim Dahlke, Dr.Med., Tatjana Zabelina, Dr.med., Francis Ayuk, Dr.med., Jens Panse, Dr.med., Heike Schieder, Dr.med., Helmut Renges, Dr.med., Djorde Atanackovic, Dr.med., Christine Wolschke, Dr.med., Axel R. Zander, Nicolaus Kroeger, PD Dr.med

Blood (2005) 106 (11): 2062.

https://doi.org/10.1182/blood.V106.11.2062.2062

Published: 2005

Journal Articles

Serum Free Light Chain [FLC] Assay in Multiple Myeloma Patients Who Achieved Negative Immunofixation after Allogeneic Stem Cell Transplantation.

Ulrike Moesbauer, Heike Schieder, MD, Helmut Renges, MD, Francis Ayuk, MD, Axel Zander, MD, Nicolaus Kröger, MD

Blood (2005) 106 (11): 2023.

https://doi.org/10.1182/blood.V106.11.2023.2023

Published: 2005

Journal Articles

Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation.

Nicolaus Kroeger, MD, Thomas Binder, MD, PhD, Heike Schieder, MD, Helmut Renges, MD, Francis Ayuk, MD, Christine Wolschke, MD, Thomas H. Eiermann, MD, PhD, Axel Zander, MD

Blood (2005) 106 (11): 2040.

https://doi.org/10.1182/blood.V106.11.2040.2040

Published: 2005

Journal Articles

Pilot Study of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.

Nicolaus Kroeger, MD, Tatjana Zabelina, MD, Heike Schieder, MD, Jens Panse, MD, Francis Ayuk, MD, Natalja Fehse, MD, Boris Fehse, MD, Olga Waschke, MD, Hans M. Kvasnicka, MD, Jurgen Thiele, MD, Axel Zander, MD

Blood (2004) 104 (11): 1512.

https://doi.org/10.1182/blood.V104.11.1512.1512

Published: 2004

Journal Articles

Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.

Nicolaus Kroeger, MD, Avichai Shimoni, MD, Maria Zagrivnaja, PhD, Francis Ayuk, MD, Michael Lioznov, PhD, Heike Schieder, MD, Boris Fehse, PhD, Tatjana Zabelina, MD, Arnon Nagler, MD, Axel Zander, MD

Blood (2004) 104 (11): 1646.

https://doi.org/10.1182/blood.V104.11.1646.1646

Published: 2004

Journal Articles

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

Nicolaus Kröger, Avichai Shimoni, Maria Zagrivnaja, Francis Ayuk, Michael Lioznov, Heike Schieder, Helmut Renges, Boris Fehse, Tatjana Zabelina, Arnon Nagler, Axel R. Zander

Blood (2004) 104 (10): 3361–3363.

https://doi.org/10.1182/blood-2004-05-2031

Published: 2004

NARROW

Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)

Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.

Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.

Serum Free Light Chain [FLC] Assay in Multiple Myeloma Patients Who Achieved Negative Immunofixation after Allogeneic Stem Cell Transplantation.

Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation.

Pilot Study of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.

Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only